SWEDISH SUMMARY: Jag projektleder i min roll på LIF (den forskande läkemedelsindustrin i Sverige) som ni säkert vet uppdrag 7.2 i den Nationella läkemedelsstrategin. Den huvudsakliga leveransen för detta projekt är en miljöbedömningsmodell för läkemedelsprodukter. Som en konsekvens av att Sofia Wallström presenterade sitt delbetänkande i Läkemedels- och Apoteksutredningen den 5 april (motsvarande uppdrag 7.1 i Nationella läkemedelsstrategin) så har vi haft möte i såväl den internationella arbetsgruppen (i fredags) och i den svenska intressentgruppen (igår) för att se hur bedömningsmodellen måste anpassas för att svara upp mot Sofias utredningsförslag.
In my role at LIF (the research-based pharmaceutical industry in Sweden) I act as you know as project manager for task 7.2 in the National Pharmaceutical Strategy (NPS). The main deliverable from the project is an environmental assessment model for pharmaceutical products. The work has been ongoing for quite some time and I have given updates regularly here at the blog (e.g. Jan 29 2013, Nov 22 2012, Dec 6 2011, and Aug 28 2011). As a consequence of the April 5 report from the Pharmaceutical and Pharmacy Inquiry, we have now had meetings both with the international group working with the model development (April 19) as well as the Swedish staleholder group (yesterday). The discussions focused the potential need for adjustments of the proposed model in order to meet the ideas presented by Sofia Wallström in the April 5 report.
Some important conclusions from Sofia’s report:
- The model should be used to environmentally differentiate between products with the same API, since green economic incentives (or environmental premiums) are proposed to be introduced within the generic substitution system (”the product of the month selection”)
- The model should use a ”life cycle perspective”, and environmental impacts from manufacturing of pharmaceuticals must be part of the scheme
- The model should possibly rather be an ”environmental assessment model” than a ”broader sustainability assessment model”, since social responsibility and CSR-aspects are not included at all in the proposed actions from the Sofia Wallström report.
With this in mind we are now continuing working on the details of the model. One thought discussed yesterday is that the ”NPS 7.2 assessment model” would be focusing environmental impacts from manufacturing primarily (e.g. API-releases, other releases/emissions to air, water and soil, and energy and climate aspects). In order to present the broader sustainability profile of the medicine, the results from the ”7.2 assessment model” would be connected to the environmental classification of the specific API (available at Fass.se) and the CSR and social sustainability data which will be accessible through the web-tool/database under development of the Swedish County Councils.
Interesting discussion to follow. It is not at all an easy project – but the process with all good discussions is extremely important to build new knowledge. I will keep you posted!